Solid-Phase Peptide Synthesis

Solid-phase peptide synthesis (SPPS) is the foundational technology enabling the commercial production of virtually all synthetic therapeutic peptides — from the simplest tripeptides to complex 40-residue analogues with multiple modifications. Understanding SPPS principles allows practitioners to appreciate the chemical complexity behind the vials they prescribe, evaluate quality claims from manufacturers, and engage meaningfully with the emerging field of peptide manufacturing quality.

The core innovation of SPPS, introduced by Robert Merrifield in 1963, was attaching the C-terminal amino acid of the target peptide sequence to an insoluble polymer support (the resin) and building the peptide chain by sequentially adding protected amino acids from C-terminus to N-terminus. Between each amino acid addition, excess reagents and byproducts are removed by washing the resin-peptide conjugate with solvent — since the growing peptide is anchored to the insoluble resin, it remains in the reaction vessel while small molecules are washed away. This elegant solution to the purification challenge of solution-phase synthesis allows sequential condensation reactions to proceed without isolating each intermediate (PMID 6390198).

The chemistry of SPPS involves three fundamental operations, repeated for each amino acid residue: (1) Deprotection — removing the temporary protecting group from the nitrogen of the last-added amino acid, making it available to react with the next amino acid. (2) Coupling — forming a new amide (peptide) bond between the deprotected amine and the carboxyl group of the next protected amino acid, using coupling reagents to activate the carboxyl group. (3) Washing — thorough washing of the resin to remove excess coupling amino acid, coupling reagents, and byproducts before the next deprotection-coupling cycle. After all residues are added (in reverse order, from C-terminus to N-terminus of the target sequence), a final global deprotection and cleavage step releases the completed peptide from the resin, along with removal of all permanent protecting groups from amino acid side chains. The crude peptide then requires purification (typically by RP-HPLC) and lyophilization before it becomes the pharmaceutical product in the vial.

The two dominant SPPS strategies — Boc (tert-butyloxycarbonyl) chemistry and Fmoc (9-fluorenylmethyloxycarbonyl) chemistry — differ primarily in the nature of the temporary alpha-amine protecting group and the conditions required to remove it. Each has advantages for specific applications, and most modern pharmaceutical peptide synthesis uses Fmoc chemistry as the standard approach. The following lessons explore both strategies, resin selection, coupling chemistry, and the downstream analytical processes that ensure the final peptide meets pharmaceutical quality standards.